By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Stem Cell Research have been published. According to news originating from Seattle, Washington, by NewsRx correspondents, research stated, "Glioblastoma Multiforme (GBM) continues to have a poor patient prognosis despite optimal standard of care. Glioma stem cells (GSCs) have been implicated as the presumed cause of tumor recurrence and resistance to therapy."
Our news journalists obtained a quote from the research from Swedish Neuroscience Institute, "With this in mind, we screened a diverse chemical library of 2,000 compounds to identify therapeutic agents that inhibit GSC proliferation and therefore have the potential to extend patient survival. High-throughput screens (HTS) identified 78 compounds that repeatedly inhibited cellular proliferation, of which 47 are clinically approved for other indications and 31 are experimental drugs. Several compounds (such as digitoxin, deguelin, patulin and phenethyl caffeate) exhibited high cytotoxicity, with half maximal inhibitory concentrations (IC50) in the low nanomolar range. In particular, the FDA approved drug for the treatment of alcoholism, disulfiram (DSF), was significantly potent across multiple patient samples (IC50 of 31.1 nM). The activity of DSF was potentiated by copper (Cu), which markedly increased GSC death. DSF-Cu inhibited the chymotrypsin-like proteasomal activity in cultured GSCs, consistent with inactivation of the ubiquitin-proteasome pathway and the subsequent induction of tumor cell death. Given that DSF is a relatively non-toxic drug that can penetrate the blood-brain barrier, we suggest that DSF should be tested (as either a monotherapy or as an adjuvant) in pre-clinical models of human GBM."
According to the news editors, the research concluded: "Data also support targeting of the ubiquitin-proteasome pathway as a therapeutic approach in the treatment of GBM."
For more information on this research see: High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget, 2012;3(10):1124-36 (see also Stem Cell Research).
The news correspondents report that additional information may be obtained from P. Hothi, The Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, United States. Additional authors for this research include T.J. Martins, L. Chen, L. Deleyrolle, J.G. Yoon, B. Reynolds and G. Foltz.
Keywords for this news article include: Seattle, Oncology, Ditiocarb, Treatment, Washington, Carbamates, Disulfides, Disulfiram, Glioblastoma, Therapeutics, United States, Carboxylic Acids, Stem Cell Research, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC